+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), Route of Administration, Application, Region, with Growth Forecasts, 2025-2030- Product Image
Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), Route of Administration, Application, Region, with Growth Forecasts, 2025-2030- Product Image
New

Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), Route of Administration, Application, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 125 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5943929
Description Jump to:
The Anticoagulants Market was valued at USD 35.96 Billion in 2024, and is projected to reach USD 47.10 Billion by 2030, rising at a CAGR of 4.80%. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights

  • Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Heparin segment is projected to experience significant growth over the forecast period.
  • Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030.
  • The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period.
  • North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. Asia-Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug category
1.2.2. Route of administration
1.2.3. Application
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug category outlook
2.2.2. Route of administration outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Anticoagulants Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Anticoagulants Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis
4.1. Drug Category Segment Dashboard
4.2. Anticoagulants Market: Drug Category Movement Analysis
4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2018 to 2030 (USD Million)
4.4. Novel Oral Anticoagulants (NOACs)
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Eliquis
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Xarelto
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Savaysa & lixiana
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Pradaxa
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Vitamin K Antagonist
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Direct Thrombin Inhibitors
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Heparin
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2. Type
4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2.2. Low Molecular Weight Heparin
4.7.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2.3. Ultra-low Molecular Weight Heparin
4.7.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2.4. Unfractionated Heparin
4.7.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3. Source
4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3.2. Porcine
4.7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3.3. Bovine
4.7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3.4. Others
4.7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis
5.1. Route of Administration Segment Dashboard
5.2. Anticoagulants Market: Route of Administration Movement Analysis
5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Oral Anticoagulants
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Injectable Anticoagulants
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis
6.1. Application Segment Dashboard
6.2. Anticoagulants Market: Application Movement Analysis
6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
6.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.5. Deep Vein Thrombosis (DVT)
6.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.6. Pulmonary Embolism
6.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.7. Other Applications
6.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2024 & 2030
7.3. Continuous bioprocessing market by Region: Key Takeaways
7.4. North America
7.4.1. U.S.
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Canada
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Mexico
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Europe
7.5.1. UK
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Germany
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. France
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Italy
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. Spain
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Asia Pacific
7.6.1. China
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. India
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Australia
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Latin America
7.7.1. Brazil
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Argentina
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.8. MEA
7.8.1. South Africa
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Saudi Arabia
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.8.4. Kuwait
7.8.4.1. Key country dynamics
7.8.4.2. Regulatory framework/ reimbursement structure
7.8.4.3. Competitive scenario
7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
8.4.1. Aspen Holdings
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Bristol-Myers Squibb Company
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. GSK plc
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Sanofi
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Bayer AG
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Boehringer Ingelheim International GmbH
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. DAIICHI SANKYO COMPANY, LIMITED
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Johnson & Johnson Services, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Eisai Co., Ltd.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global anticoagulants market, by region, 2018-2030 (USD Million)
Table 3 Global anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 4 Global anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 5 Global anticoagulants market, by application, 2018-2030 (USD Million)
Table 6 North America anticoagulants market, by country, 2018-2030 (USD Million)
Table 7 North America anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 8 North America anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 9 North America anticoagulants market, by application, 2018-2030 (USD Million)
Table 10 U.S. anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 11 U.S. anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 12 U.S. anticoagulants market, by application, 2018-2030 (USD Million)
Table 13 Canada anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 14 Canada anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 15 Canada anticoagulants market, by application, 2018-2030 (USD Million)
Table 16 Mexico anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 17 Mexico anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 18 Mexico anticoagulants market, by application, 2018-2030 (USD Million)
Table 19 Europe anticoagulants market, by country, 2018-2030 (USD Million)
Table 20 Europe anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 21 Europe anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 22 Europe anticoagulants market, by application, 2018-2030 (USD Million)
Table 23 Germany anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 24 Germany anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 25 Germany anticoagulants market, by application, 2018-2030 (USD Million)
Table 26 UK anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 27 UK anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 28 UK anticoagulants market, by application, 2018-2030 (USD Million)
Table 29 France anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 30 France anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 31 France anticoagulants market, by application, 2018-2030 (USD Million)
Table 32 Italy anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 33 Italy anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 34 Italy anticoagulants market, by application, 2018-2030 (USD Million)
Table 35 Spain anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 36 Spain anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 37 Spain anticoagulants market, by application, 2018-2030 (USD Million)
Table 38 Asia Pacific anticoagulants market, by country, 2018-2030 (USD Million)
Table 39 Asia Pacific anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 40 Asia Pacific anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 41 Asia Pacific anticoagulants market, by application, 2018-2030 (USD Million)
Table 42 China anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 43 China anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 44 China anticoagulants market, by application, 2018-2030 (USD Million)
Table 45 Japan anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 46 Japan anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 47 Japan anticoagulants market, by application, 2018-2030 (USD Million)
Table 48 India anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 49 India anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 50 India anticoagulants market, by application, 2018-2030 (USD Million)
Table 51 South Korea anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 52 South Korea anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 53 South Korea anticoagulants market, by application, 2018-2030 (USD Million)
Table 54 Australia anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 55 Australia anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 56 Australia anticoagulants market, by application, 2018-2030 (USD Million)
Table 57 Latin America anticoagulants market, by country, 2018-2030 (USD Million)
Table 58 Latin America anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 59 Latin America anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 60 Latin America anticoagulants market, by application, 2018-2030 (USD Million)
Table 61 Brazil anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 62 Brazil anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 63 Brazil surgical anticoagulants market, by application, 2018-2030 (USD Million)
Table 64 Argentina anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 65 Argentina anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 66 Argentina surgical anticoagulants market, by application, 2018-2030 (USD Million)
Table 67 MEA anticoagulants market, by region, 2018-2030 (USD Million)
Table 68 MEA anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 69 MEA anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 70 MEA anticoagulants market, by application, 2018-2030 (USD Million)
Table 71 South Africa anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 72 South Africa anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 73 South Africa anticoagulants market, by application, 2018-2030 (USD Million)
Table 74 Saudi Arabia anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 75 Saudi Arabia anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 76 Saudi Arabia anticoagulants market, by application, 2018-2030 (USD Million)
Table 77 UAE anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 78 UAE anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 79 UAE anticoagulants market, by application, 2018-2030 (USD Million)
Table 80 Kuwait anticoagulants market, by drug category, 2018-2030 (USD Million)
Table 81 Kuwait anticoagulants market, by route of administration, 2018-2030 (USD Million)
Table 82 Kuwait anticoagulants market, by application, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Anticoagulants market: market outlook
Figure 10 Anticoagulants competitive insights
Figure 11 Parent market outlook
Figure 12 Related/ancillary market outlook
Figure 13 Penetration and growth prospect mapping
Figure 14 Industry value chain analysis
Figure 15 Anticoagulants market driver impact
Figure 16 Anticoagulants market restraint impact
Figure 17 Anticoagulants market strategic initiatives analysis
Figure 18 Anticoagulants market: Drug category movement analysis
Figure 19 Anticoagulants market: Drug category outlook and key takeaways
Figure 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2018-2030
Figure 21 Eliquis market estimates and forecast, 2018-2030
Figure 22 Xarelto market estimates and forecast, 2018-2030
Figure 23 Savaysa & lixiana market estimates and forecast, 2018-2030
Figure 24 Pradaxa market estimates and forecast, 2018-2030
Figure 25 Vitamin K Antagonist market estimates and forecast, 2018-2030
Figure 26 Direct Thrombin Inhibitors market estimates and forecast, 2018-2030
Figure 27 Heparin market estimates and forecast, 2018-2030
Figure 28 Low molecular weight heparin market estimates and forecast, 2018-2030
Figure 29 Ultra-low molecular weight heparin market estimates and forecast, 2018-2030
Figure 30 Unrationed heparin market estimates and forecast, 2018-2030
Figure 31 Heparin sources market estimates and forecast, 2018-2030
Figure 32 Porcine-based heparin market estimates and forecast, 2018-2030
Figure 33 Bovine-based heparin market estimates and forecast, 2018-2030
Figure 34 Other heparin market estimates and forecast, 2018-2030
Figure 35 Others market estimates and forecast, 2018-2030
Figure 36 Anticoagulants Market: Route of administration movement Analysis
Figure 37 Anticoagulants market: Route of administration outlook and key takeaways
Figure 38 Oral anticoagulants market estimates and forecasts, 2018-2030
Figure 39 Injectable anticoagulants market estimates and forecasts,2018-2030
Figure 40 Anticoagulants market: Application movement analysis
Figure 41 Anticoagulants market: Application outlook and key takeaways
Figure 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2018-2030
Figure 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018-2030
Figure 44 Pulmonary embolism market estimates and forecasts, 2018-2030
Figure 45 Other applications market estimates and forecasts,2018-2030
Figure 46 Global anticoagulants market: Regional movement analysis
Figure 47 Global anticoagulants market: Regional outlook and key takeaways
Figure 48 North America market estimates and forecasts, 2018-2030
Figure 49 U.S. market estimates and forecasts, 2018-2030
Figure 50 Canada market estimates and forecasts, 2018-2030
Figure 51 Mexico market estimates and forecasts, 2018-2030
Figure 52 Europe market estimates and forecasts, 2018-2030
Figure 53 UK market estimates and forecasts, 2018-2030
Figure 54 Germany market estimates and forecasts, 2018-2030
Figure 55 France market estimates and forecasts, 2018-2030
Figure 56 Italy market estimates and forecasts, 2018-2030
Figure 57 Spain market estimates and forecasts, 2018-2030
Figure 58 Asia Pacific market estimates and forecasts, 2018-2030
Figure 59 China market estimates and forecasts, 2018-2030
Figure 60 Japan market estimates and forecasts, 2018-2030
Figure 61 India market estimates and forecasts, 2018-2030
Figure 62 South Korea market estimates and forecasts, 2018-2030
Figure 63 Australia market estimates and forecasts, 2018-2030
Figure 64 Latin America market estimates and forecasts, 2018-2030
Figure 65 Brazil market estimates and forecasts, 2018-2030
Figure 66 Argentina market estimates and forecasts, 2018-2030
Figure 67 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 68 South Africa market estimates and forecasts, 2018-2030
Figure 69 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 70 UAE market estimates and forecasts, 2018-2030
Figure 71 Kuwait market estimates and forecasts, 2018-2030

Companies Mentioned

The companies profiled in this Anticoagulants market report include:
  • Aspen Holdings
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • GSK plc
  • Sanofi
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • DAIICHI SANKYO COMPANY, LIMITED
  • Johnson & Johnson Services, Inc.
  • Eisai Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages125
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 35.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 47.1 Billion
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel, Dosage Form - Global Forecast to 2030 - Product Image

Anticoagulants Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel, Dosage Form - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Anticoagulant Reversal Drugs Market by Reversal Agent Type, Route of Administration, End User, Distribution Channel, Application, Dosage Form - Global Forecast to 2030 - Product Image

Anticoagulant Reversal Drugs Market by Reversal Agent Type, Route of Administration, End User, Distribution Channel, Application, Dosage Form - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Anticoagulants Market Report by Drug Class, and Region 2024-2032 - Product Image

Anticoagulants Market Report by Drug Class, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Anticoagulants Market 2024-2028 - Product Image

Anticoagulants Market 2024-2028

  • Report
  • 177 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.